FDA’s New Plausible Mechanism Pathway: How It Compares to Existing Approval Routes

On November 12, 2025, FDA leadership introduced the Plausible Mechanism (PM) Pathway, a proposed regulatory approach designed to accelerate access to highly individualized therapies, particularly for ultra-rare genetic diseases where traditional clinical trials are nearly impossible. This pathway reflects a growing need for flexible frameworks that can support gene-editing, bespoke therapeutics, and N-of-1 treatments. But how does it compare to the FDA’s existing approval mechanisms?

Below is an overview of what the Plausible Mechanism Pathway offers and how it differs from current regulatory options such as traditional approval, accelerated approval, expedited programs, and emergency access routes.

What Is the Plausible Mechanism Pathway?

The PM Pathway is built for situations where a disease is caused by a clearly defined genetic or molecular abnormality and the therapy directly targets that abnormality. Approval may be based on a small number of patients showing:

• Strong evidence of biological plausibility
• Demonstrated target engagement through biomarkers or molecular assays
• Meaningful clinical improvement
• A well-understood natural history of the disease

Instead of requiring large randomized trials, FDA could grant approval after “several consecutive” successful cases, with the expectation of rigorous post-market real-world evidence collection.

This pathway addresses gaps in today’s regulatory ecosystem where bespoke therapies are scientifically viable but lack a realistic path to licensure.

Traditional FDA Approval vs. the PM Pathway

Traditional approval requires substantial evidence of effectiveness from adequate and well-controlled studies, typically randomized controlled trials. This is the gold standard for confidence but often impractical for one-in-a-million disorders or genotype-specific therapies.

Key difference:

• Traditional approval demands robust pre-market data.
• The PM Pathway accepts a much smaller pre-market dataset when the mechanism is clear and the therapy is highly individualized.

Accelerated Approval vs. the PM Pathway

Accelerated approval allows the FDA to approve therapies based on surrogate endpoints reasonably likely to predict clinical benefit. Confirmatory trials are required post-approval.

How PM is different:

Accelerated approval still assumes population-level data and validated or plausible surrogate markers.

The PM Pathway centers on mechanistic plausibility and direct clinical responses in a very small number of patients, eliminating the need for conventional trial sizes.

• PM requires even stronger post-market evidence given the smaller pre-market dataset.
• For gene therapies, rare diseases, and individualized editing, PM may fill a regulatory gap accelerated approval cannot.
• Expedited Programs vs. the PM Pathway

FDA’s expedited programs (Fast Track, Breakthrough Therapy, Priority Review, and RMAT) offer tools to speed development and review. However, they do not change the evidentiary standard required for approval.

Contrast with PM:

• Expedited programs accelerate timelines.
• PM changes the evidence model, enabling approval based on mechanistic rationale and small-N clinical results.

PM is therefore a new evidentiary pathway, not just a procedural accelerator.

EUA, Expanded Access, and Single-Patient IND vs. the PM Pathway

Emergency Use Authorizations (EUAs) and Expanded Access pathways provide temporary or compassionate access to unapproved treatments. These are not approval routes and do not result in a marketing license.

How PM differs:

• PM is designed to lead to full marketing authorization.
• The evidence is structured and prospectively collected, even if small.
• It emphasizes long-term follow-up, safety monitoring, and real-world performance.

How the Plausible Mechanism Pathway Could Shape Future Approvals

The PM Pathway represents a major shift toward regulatory flexibility for modern precision therapies. If implemented, it could:

• Accelerate access for patients with ultra-rare diseases
• Provide clearer guidance for bespoke gene-editing and individualized therapeutics
• Modernize the evidence framework around single-patient or small-cohort interventions
• Ensure robust post-market learning through real-world data

At the same time, payers, clinicians, and developers will need to adapt to a model where post-market data carries far more weight than in traditional approval.

As precision medicine advances, the Plausible Mechanism Pathway may become a cornerstone for next-generation therapies.